Midazolam
FDA-approved product (spray, nasal), marketed as Midazolam In 0.8% Sodium Chloride, Midazolam In 0.9% Sodium Chloride, Nayzilam and 6 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Amnesia
- Epilepsy
- Seizure
- Status epilepticus
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Benzodiazepine derivatives
- FDA pharmacologic class
- Benzodiazepine FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli35.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae18.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Midazolam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Impact of Sedation Practices on Clinical Outcomes Among Mechanically Ventilated Children
NCT07821268 · start 2026-09-01
Registered record
- Registry ID
- NCT07821268
- Conditions
- Mechanically Ventilated Children Admitted to the Pediatric Intensive Care Unit
- Interventions
- no need
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Not yet recruiting
- Start
- 2026-09-01
- Completion
- 2027-06-01
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMechanically Ventilated Children Admitted to the Pediatric Intensive Care UnitInterventionno needPhaseNot recordedRegistry statusNot yet recruitingA Trial of Lu AH69593 in Healthy Participants
NCT07775261 · start 2026-08-27
Registered record
- Registry ID
- NCT07775261
- Conditions
- Healthy Participants
- Interventions
- Lu AH69593; Itraconazole; Carbamazepine; Midazolam
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Not yet recruiting
- Start
- 2026-08-27
- Completion
- 2026-11-06
- Enrolment
- 46
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy ParticipantsInterventionLu AH69593; Itraconazole; Carbamazepine; MidazolamPhasePhase 1Registry statusNot yet recruitingAn Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
NCT07426757 · start 2026-07-01
Registered record
- Registry ID
- NCT07426757
- Conditions
- Advanced Malignancies; Advanced Cancer
- Interventions
- PF-07994525; Midazolam
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Recruiting
- Start
- 2026-07-01
- Completion
- 2030-07-10
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Malignancies; Advanced CancerInterventionPF-07994525; MidazolamPhasePhase 1Registry statusRecruitingComparing Two Doses of Midazolam With Added Dexmedetomidine for Kids Before Surgery
NCT06979791 · start 2025-06-01
Registered record
- Registry ID
- NCT06979791
- Conditions
- Preoperative Anxiety Experienced by the Pediatric Patient; Preoperative Anxiety
- Interventions
- Dexmedetomidine + Midazolam 0.4 mg/kg; Dexmedetomidine + Midazolam 0.2 mg/kg
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2025-06-01
- Completion
- 2026-06-01
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPreoperative Anxiety Experienced by the Pediatric Patient; Preoperative AnxietyInterventionDexmedetomidine + Midazolam 0.4 mg/kg; Dexmedetomidine + Midazolam 0.2 mg/kgPhasePhase 2Registry statusCompletedMidazolam or Fentanyl as Adjuvants to Epidural Bupivacaine Plus Dexamethasone for Analgesia
NCT06898697 · start 2025-04-01
Registered record
- Registry ID
- NCT06898697
- Conditions
- Lumbar Spine Fixation
- Interventions
- Epidural fentanyl; epidural midazolam
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2025-04-01
- Completion
- 2025-12-01
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLumbar Spine FixationInterventionEpidural fentanyl; epidural midazolamPhaseNot applicableRegistry statusCompletedAn Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
NCT06686628 · start 2024-11-20
Registered record
- Registry ID
- NCT06686628
- Conditions
- Dermatitis Atopic
- Interventions
- Amlitelimab; Midazolam; Caffeine; Metoprolol; Omeprazole; Warfarin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2024-11-20
- Completion
- 2026-04-02
- Enrolment
- 23
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDermatitis AtopicInterventionAmlitelimab; Midazolam; Caffeine; Metoprolol +2 morePhasePhase 1Registry statusCompletedComparison Between the Effect of Dexmedetomidine _midazolam and ketamine_midazolam Combination
NCT07074262 · start 2024-10-10
Registered record
- Registry ID
- NCT07074262
- Conditions
- Postoperative Cognitive Dysfunction; Post Operative Delirium
- Interventions
- Ketamine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2024-10-10
- Completion
- 2025-03-10
- Enrolment
- 114
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostoperative Cognitive Dysfunction; Post Operative DeliriumInterventionKetaminePhaseNot applicableRegistry statusCompletedAnesthesia and Non-small Cell Lung Cancer Recurrence
NCT06330038 · start 2024-08-05
Registered record
- Registry ID
- NCT06330038
- Conditions
- Non-small Cell Lung Cancer; Surgery; Anesthesia
- Interventions
- Propofol; Inhaled anesthetics
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Recruiting
- Start
- 2024-08-05
- Completion
- 2028-12-31
- Enrolment
- 5,384
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-small Cell Lung Cancer; Surgery; AnesthesiaInterventionPropofol; Inhaled anestheticsPhasePhase 4Registry statusRecruitingECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants
NCT06293742 · start 2024-02-08
Registered record
- Registry ID
- NCT06293742
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- ECC5004; Midazolam; Rosuvastatin; Digoxin; Atorvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2024-02-08
- Completion
- 2024-04-15
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionType 2 Diabetes MellitusInterventionECC5004; Midazolam; Rosuvastatin; Digoxin +1 morePhasePhase 1Registry statusCompletedA Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553
NCT06105255 · start 2023-05-24
Registered record
- Registry ID
- NCT06105255
- Conditions
- Healthy Male
- Interventions
- D-1553
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2023-05-24
- Completion
- 2024-02-02
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy MaleInterventionD-1553PhasePhase 1Registry statusCompletedSupraclavicular Block vs Bier's Block for Forearm Trauma Surgery
NCT07418086 · start 2023-04-01
Registered record
- Registry ID
- NCT07418086
- Conditions
- Forearm Fractures
- Interventions
- Bier's Block (IVRA); Supraclavicular Block
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2023-04-01
- Completion
- 2024-02-01
- Enrolment
- 66
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionForearm FracturesInterventionBier's Block (IVRA); Supraclavicular BlockPhaseNot applicableRegistry statusCompletedImpact of Virtual Reality Hypno-sedation on Functional Recovery and Anxiety in Foot Surgery With Regional Anesthesia
NCT05558449 · start 2022-11-28
Registered record
- Registry ID
- NCT05558449
- Conditions
- Foot Deformities; Regional Anesthesia Morbidity; Valgus; Hallux; Analgesia
- Interventions
- Hypnosedation; Midazolam injection; Virtual reality
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2022-11-28
- Completion
- 2023-10-16
- Enrolment
- 57
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFoot Deformities; Regional Anesthesia Morbidity; Valgus; Hallux +1 moreInterventionHypnosedation; Midazolam injection; Virtual realityPhasePhase 4Registry statusCompletedA Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers
NCT05392127 · start 2022-07-15
Registered record
- Registry ID
- NCT05392127
- Conditions
- Rheumatoid Arthritis
- Interventions
- SHR0302 Tablets; Midazolam Maleate Tablets; Warfarin Sodium Tablets; Omeprazole Enteric Capsules; Vitamin K1 Tablets; Repaglinide Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2022-07-15
- Completion
- 2022-08-18
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRheumatoid ArthritisInterventionSHR0302 Tablets; Midazolam Maleate Tablets; Warfarin Sodium Tablets; Omeprazole Enteric Capsules +2 morePhasePhase 1Registry statusCompletedEffectiveness of Combined Levetiracetam and Midazolam in Generalized Convulsive Status Epilepticus in Children
NCT04926844 · start 2021-06-20
Registered record
- Registry ID
- NCT04926844
- Conditions
- Status Epilepticus; Generalized Convulsive Status Epilepticus; Status Epilepticus, Generalized; Status Epilepticus, Generalized Convulsive
- Interventions
- Levetiracetam; Midazolam; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2021-06-20
- Completion
- 2022-09-01
- Enrolment
- 144
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStatus Epilepticus; Generalized Convulsive Status Epilepticus; Status Epilepticus, Generalized; Status Epilepticus, Generalized ConvulsiveInterventionLevetiracetam; Midazolam; PlaceboPhasePhase 2Registry statusCompletedA Study of LY3484356 in Healthy Female Participants
NCT04840888 · start 2021-04-26
Registered record
- Registry ID
- NCT04840888
- Conditions
- Healthy
- Interventions
- LY3484356; Omeprazole; Itraconazole; Carbamazepine; Midazolam
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2021-04-26
- Completion
- 2022-04-12
- Enrolment
- 82
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionLY3484356; Omeprazole; Itraconazole; Carbamazepine +1 morePhasePhase 1Registry statusCompleted